» Articles » PMID: 27526293

Histologic Spectrum of Giant Cell Tumor (GCT) of Bone in Patients 18 Years of Age and Below: A Study of 63 Patients

Overview
Date 2016 Aug 16
PMID 27526293
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Although the majority of giant cell tumors (GCTs) of the bone occur in adult patients, occasionally they arise in the pediatric population. In this setting they may be mistaken for tumors more commonly seen in this age group, including osteosarcoma, aneurysmal bone cyst, and chondroblastoma. All cases of primary GCT of the bone arising in patients 18 years and below were retrieved from our institutional archives and examined with emphasis on the evaluation of various morphologic patterns. Clinical/radiologic records were reviewed when available. Analysis for H3F3A/H3F3B mutations was performed in a subset of cases. Sixty-three (of 710) patients treated at our institution for GCT were 18 years of age and below. The following morphologic patterns were identified: fibrosis (31 cases, 49%), reactive-appearing bone (26, 41%), cystic change (7, 11%), foamy histiocytes (6, 10%), secondary aneurysmal bone cyst (3, 5%), and cartilage (2, 3%). Infarct-like necrosis was present in 17 tumors (27%), and the mitotic rate ranged from 0 to 35 mitoses/10 high-power fields (median 5 mitoses/10 high-power field). Follow-up information (n=55; 6 mo to 69.6 y; median, 11.6 y) showed 21 patients with local recurrence (38%) and 2 patients with lung metastasis (4%). Polymerase chain reaction with sequencing showed that 5 of 5 tested cases harbored H3F3A mutations. In summary, GCT arising in the pediatric population is rare, representing 9% of GCTs seen at our institution. The morphologic spectrum of these tumors is broad and similar to that seen in patients above 18 years of age. It is important to recognize that matrix formation may be observed in GCT, including reactive-appearing bone and cartilage, as well as areas of fibrosis mimicking osteoid production, to avoid misclassification as osteosarcoma or other giant cell-rich lesions common in children.

Citing Articles

Management and surveillance of metastatic giant cell tumour of bone.

Fellows D, Kotowska J, Stevenson T, Brown J, Orosz Z, Siddiqi A Pathol Oncol Res. 2025; 31:1611916.

PMID: 40046036 PMC: 11879744. DOI: 10.3389/pore.2025.1611916.


Surgical Treatments and Long-Term Outcomes for Pediatric Patients With Lumbar Spinal Tumors.

Zhang Y, Chen W, Cao S, He S, Wei H Global Spine J. 2023; 15(2):808-817.

PMID: 38060695 PMC: 11877547. DOI: 10.1177/21925682231212863.


The efficacy and safety of short-course neoadjuvant denosumab for en bloc spondylectomy in spinal giant cell tumor of bone: a preliminary report.

Tang Q, Lu J, Zhu X, Song G, Wu H, Xu H Eur Spine J. 2023; 32(12):4297-4305.

PMID: 37318598 DOI: 10.1007/s00586-023-07770-w.


Diagnostic value of mutation and clinicopathological features of giant cell tumours in non-long bones.

Luo Y, Tang J, Huang J, Hu D, Bai Y, Chen J J Bone Oncol. 2023; 38:100467.

PMID: 36619849 PMC: 9813520. DOI: 10.1016/j.jbo.2022.100467.


Giant cell tumor of bone: An update, including spectrum of pathological features, pathogenesis, molecular profile and the differential diagnoses.

Rekhi B, Dave V Histol Histopathol. 2022; 38(2):139-153.

PMID: 35766228 DOI: 10.14670/HH-18-486.